These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 12576441

  • 1. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
    Linderoth J, Jerkeman M, Cavallin-Ståhl E, Kvaløy S, Torlakovic E, Nordic Lymphoma Group Study.
    Clin Cancer Res; 2003 Feb; 9(2):722-8. PubMed ID: 12576441
    [Abstract] [Full Text] [Related]

  • 2. Cluster analysis of apoptosis-associated bcl2 family proteins in diffuse large B-cell lymphomas. Relations with the apoptotic index, the proliferation profile and the B-cell differentiation immunophenotypes.
    Bai M, Skyrlas A, Agnantis NJ, Kamina S, Kitsoulis P, Kanavaros P.
    Anticancer Res; 2004 Feb; 24(5A):3081-8. PubMed ID: 15517919
    [Abstract] [Full Text] [Related]

  • 3. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
    Zinzani PL, Dirnhofer S, Sabattini E, Alinari L, Piccaluga PP, Stefoni V, Tani M, Musuraca G, Marchi E, Falini B, Baccarani M, Pileri SA.
    Haematologica; 2005 Mar; 90(3):341-7. PubMed ID: 15749666
    [Abstract] [Full Text] [Related]

  • 4. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Enblad G, Leppä S.
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [Abstract] [Full Text] [Related]

  • 5. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, Shi X, Hans CP, Greiner TC, Bierman PJ, Bociek RG, Armitage JO, Chan WC, Vose JM.
    J Clin Oncol; 2008 Oct 01; 26(28):4587-94. PubMed ID: 18662967
    [Abstract] [Full Text] [Related]

  • 6. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
    Jerkeman M, Anderson H, Dictor M, Kvaløy S, Akerman M, Cavallin-Ståhl E, Nordic Lymphoma Group study.
    Ann Hematol; 2004 Jul 01; 83(7):414-9. PubMed ID: 15085385
    [Abstract] [Full Text] [Related]

  • 7. Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas.
    King BE, Chen C, Locker J, Kant J, Okuyama K, Falini B, Swerdlow SH.
    Mod Pathol; 2000 Nov 01; 13(11):1219-31. PubMed ID: 11106080
    [Abstract] [Full Text] [Related]

  • 8. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi.
    Morabito F, Gallamini A, Stelitano C, Callea V, Guglielmi C, Neri S, Lazzaro A, Orsucci L, Ilariucci F, Sacchi S, Vitolo U, Federico M.
    Cancer; 2004 Oct 01; 101(7):1601-8. PubMed ID: 15378507
    [Abstract] [Full Text] [Related]

  • 9. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
    Espinosa I, Briones J, Bordes R, Brunet S, Martino R, Sureda A, Prat J, Sierra J.
    Ann Hematol; 2006 Sep 01; 85(9):597-603. PubMed ID: 16830142
    [Abstract] [Full Text] [Related]

  • 10. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
    Sohn SK, Jung JT, Kim DH, Kim JG, Kwak EK, Park Ti, Shin DG, Sohn KR, Lee KB.
    Am J Hematol; 2003 Jun 01; 73(2):101-7. PubMed ID: 12749011
    [Abstract] [Full Text] [Related]

  • 11. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.
    Braaten KM, Betensky RA, de Leval L, Okada Y, Hochberg FH, Louis DN, Harris NL, Batchelor TT.
    Clin Cancer Res; 2003 Mar 01; 9(3):1063-9. PubMed ID: 12631608
    [Abstract] [Full Text] [Related]

  • 12. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
    Yamaguchi M, Nakamura N, Suzuki R, Kagami Y, Okamoto M, Ichinohasama R, Yoshino T, Suzumiya J, Murase T, Miura I, Ohshima K, Nishikori M, Tamaru J, Taniwaki M, Hirano M, Morishima Y, Ueda R, Shiku H, Nakamura S.
    Haematologica; 2008 Aug 01; 93(8):1195-202. PubMed ID: 18556402
    [Abstract] [Full Text] [Related]

  • 13. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
    Liu YH, Xu FP, Zhuang HG, Lai KC, Xie D, Luo DL, Li L, Luo XL, Xu J, Zhang MH, Zhang F, Li HM.
    Hum Pathol; 2008 Jun 01; 39(6):875-84. PubMed ID: 18440593
    [Abstract] [Full Text] [Related]

  • 14. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
    Muris JJ, Meijer CJ, Vos W, van Krieken JH, Jiwa NM, Ossenkoppele GJ, Oudejans JJ.
    J Pathol; 2006 Apr 01; 208(5):714-23. PubMed ID: 16400625
    [Abstract] [Full Text] [Related]

  • 15. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY, Yong WB, Zhu J, Zheng W, Zhang YT, Wang XP, Meng SN.
    Zhonghua Zhong Liu Za Zhi; 2005 Mar 01; 27(3):174-6. PubMed ID: 15946571
    [Abstract] [Full Text] [Related]

  • 16. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS.
    J Clin Oncol; 2008 Jan 20; 26(3):447-54. PubMed ID: 18086797
    [Abstract] [Full Text] [Related]

  • 17. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Hasselblom S, Hansson U, Olsson M, Torén L, Bergström A, Nilsson-Ehle H, Andersson PO.
    Br J Haematol; 2010 May 20; 149(4):560-8. PubMed ID: 20201946
    [Abstract] [Full Text] [Related]

  • 18. CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses.
    Biasoli I, Morais JC, Scheliga A, Milito CB, Romano S, Land M, Pulcheri W, Spector N.
    Histopathology; 2005 Mar 20; 46(3):328-33. PubMed ID: 15720419
    [Abstract] [Full Text] [Related]

  • 19. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.
    Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S.
    Haematologica; 2008 Feb 20; 93(2):193-200. PubMed ID: 18223287
    [Abstract] [Full Text] [Related]

  • 20. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, Lin TY, Lu TX.
    Ai Zheng; 2006 Dec 20; 25(12):1543-9. PubMed ID: 17166383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.